THE HEALTH EQUITY STRATEGIES GROUP, LLC

Lobbying for TRAVERE THERAPEUTICS · Pharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $16,000.00 income · posted Aug 4, 2026

Lobbying activity 4

Health Issues

Rare kidney disease

Medical/Disease Research/Clinical Labs

Rare kidney disease

Medicare/Medicaid

Rare kidney disease

Pharmacy

Rare kidney disease

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.